The Technical Analyst
Select Language :
Replimune Group Inc [REPL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Replimune Group Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Replimune Group Inc is listed at the  Exchange

7.28% $8.25

America/New_York / 27 mar 2024 @ 16:00


Replimune Group Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 506.45 mill
EPS: -3.16
P/E: -2.61
Earnings Date: May 16, 2024
SharesOutstanding: 61.39 mill
Avg Daily Volume: 1.475 mill
RATING 2024-03-27
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Neutral
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.61 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.44x
Company: PE -2.61 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.474
(-82.13%) $-6.78
Date: 2024-03-28
Expected Trading Range (DAY)

$ 7.75 - 8.75

( +/- 6.05%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-11-16 Xynos Konstantinos Sell 7 313 Common Stock
2023-11-16 Sarchi Christopher Sell 5 255 Common Stock
2023-09-18 Hill Emily Luisa Buy 125 000 Employee Stock Option (right to buy)
2023-09-18 Hill Emily Luisa Buy 83 330 Common Stock
2023-09-18 Hill Emily Luisa Buy 0
INSIDER POWER
54.14
Last 98 transactions
Buy: 2 285 388 | Sell: 489 465

Forecast: 16:00 - $8.23

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $8.23
Forecast 2: 16:00 - $8.23
Forecast 3: 16:00 - $8.23
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $8.25 (7.28% )
Volume 0.991 mill
Avg. Vol. 1.475 mill
% of Avg. Vol 67.15 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Replimune Group Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Replimune Group Inc

RSI

Intraday RSI14 chart for Replimune Group Inc

Last 10 Buy & Sell Signals For REPL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$7.81N/AActive
Profile picture for
            Replimune Group Inc

REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Last 10 Buy Signals

Date Signal @
XVSUSDMar 28 - 04:18$16.42
XMRUSDMar 28 - 04:18$138.05
WMNTUSDMar 28 - 04:151.200
FTNUSDMar 28 - 04:171.820
API3USDMar 28 - 04:173.83
NEL.OLMar 27 - 08:08NOK4.83
BURGERUSDMar 28 - 04:130.878
PHBUSDMar 28 - 04:142.76
MPLUSDMar 28 - 04:1323.79
ORAIUSDMar 28 - 04:1314.59

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.